Structure Therapeutics Announces Positive Topline Data from Obesity Studies
Global biopharmaceutical company, Structure Therapeutics Inc. (Nasdaq: GPCR), has officially entered the obesity therapeutics race this week. The company’s shares climbed after it announced positive 12-week topline obesity data from its Phase 2a study of GSBR-1290, and positive topline results from its capsule to tablet PK study. Structure said that both studies achieved their primary and secondary objectives.
Raymond Stevens, Ph.D., Founder and CEO of Structure said that the company is on track to initiate a 36-week Phase 2b study in obesity in Q4 2024.
“These topline results demonstrate the substantial weight loss effect of GSBR-1290 and its potential to become a best-in-class oral small molecule GLP-1RA as well as an ideal backbone for future combination therapeutics for the treatment of obesity and related diseases. We designed GSBR-1290 to be dosed once-a-day, and are pleased to see the competitive treatment effect at 12 weeks, dose proportional exposure and target engagement over 24 hours.”
At 12 weeks, GSBR-1290 achieved a clinically meaningful and statistically significant placebo-adjusted mean weight loss of 6.2% in the Phase 2a obesity study and up to 6.9% in the capsule to tablet PK study.
GSBR-1290 demonstrated favorable safety and tolerability results with low adverse effects-related study discontinuations.
Obesity affects approximately 800 million people worldwide, including 670 million adults and 120 million children and adolescents. There is a growing unmet need for oral treatments for obesity that are cost-effective, easy to make at scale, and more stable in order to be easier to transport and store.
About Structure Therapeutics
Structure Therapeutics is a science-driven clinical-stage biopharmaceutical company focused on discovering and developing innovative oral small molecule treatments for chronic metabolic and cardiopulmonary conditions with significant unmet medical needs. Utilizing its next generation structure-based drug discovery platform, the Company has established a robust GPCR-targeted pipeline, featuring multiple wholly-owned proprietary clinical-stage small molecule compounds designed to surpass the manufacturing scalability limitations of traditional biologic and peptide therapies and be accessible to more patients around the world. For additional information, please visit www.structuretx.com.
